KMT2C and breast carcinoma: We note that not all KMT2C mutations seen in breast cancer will recapitulate loss of function but given that over 55% of KMT2C mutations are truncation mutations and given the lack of a specific hotspot mutation, our KMT2C knockdown cells provided a key model to study the functional role of KMT2C in breast cancer.